Clearside Biomedical Inc. is counting on the uveitis indication for its ophthalmic drug Xipere to be enough to keep the company commercially afloat, following the drug's failure in a Phase III study in retinal vein occlusion.
Alpharetta, Ga
Clearside Says Uveitis Indication For Xipere Would Keep Company Afloat
Following failure and discontinuation of Phase III studies in retinal vein occlusion, company says it will have enough cash to get through 2020.
More from R&D
More from Scrip
• By
Company surprises investors with Jørgensen's exit but insists its strategy will not change.
• By
The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.
Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.